Etrasimod arginine is in development for the treatment of immune-mediated diseases, including ulcerative colitis. A clinical trial (NCT03945188 and NCT03996369) is ongoing to investigate the effect of etrasimod for the treatment of moderately to severely active ulcerative colitis. Etrasimod arginine, also known as APD334, is an investigational oral medication that acts as a full agonist on sphingosine-1-phosphate (S1P)1, S1P4, and S1P5 receptors. It is currently being developed to address conditions associated with immune responses and inflammation. Etrasimod arginine has also shown inhibitory effects on pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6, and IL-17A, while enhancing the activity of the anti-inflammatory cytokine IL-10.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Etrasimod Arginine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.